JP2018508214A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508214A5
JP2018508214A5 JP2017546081A JP2017546081A JP2018508214A5 JP 2018508214 A5 JP2018508214 A5 JP 2018508214A5 JP 2017546081 A JP2017546081 A JP 2017546081A JP 2017546081 A JP2017546081 A JP 2017546081A JP 2018508214 A5 JP2018508214 A5 JP 2018508214A5
Authority
JP
Japan
Prior art keywords
binding molecule
acid sequence
seq
amino acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508214A (ja
JP6793655B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020920 external-priority patent/WO2016141303A2/en
Publication of JP2018508214A publication Critical patent/JP2018508214A/ja
Publication of JP2018508214A5 publication Critical patent/JP2018508214A5/ja
Application granted granted Critical
Publication of JP6793655B2 publication Critical patent/JP6793655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546081A 2015-03-04 2016-03-04 Cd20結合分子およびその使用方法 Active JP6793655B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128284P 2015-03-04 2015-03-04
US62/128,284 2015-03-04
PCT/US2016/020920 WO2016141303A2 (en) 2015-03-04 2016-03-04 Cd20 binding molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020186950A Division JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018508214A JP2018508214A (ja) 2018-03-29
JP2018508214A5 true JP2018508214A5 (enExample) 2019-04-11
JP6793655B2 JP6793655B2 (ja) 2020-12-02

Family

ID=56849117

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017546081A Active JP6793655B2 (ja) 2015-03-04 2016-03-04 Cd20結合分子およびその使用方法
JP2020186950A Pending JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法
JP2023078176A Pending JP2023099206A (ja) 2015-03-04 2023-05-10 Cd20結合分子およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020186950A Pending JP2021036885A (ja) 2015-03-04 2020-11-10 Cd20結合分子およびその使用方法
JP2023078176A Pending JP2023099206A (ja) 2015-03-04 2023-05-10 Cd20結合分子およびその使用方法

Country Status (18)

Country Link
US (2) US10787520B2 (enExample)
EP (2) EP3957738A1 (enExample)
JP (3) JP6793655B2 (enExample)
KR (4) KR20220018081A (enExample)
CN (2) CN107532188B (enExample)
AU (3) AU2016226060B2 (enExample)
BR (1) BR112017018941B8 (enExample)
CA (1) CA2978324A1 (enExample)
DK (1) DK3265575T3 (enExample)
ES (1) ES2874558T3 (enExample)
HU (1) HUE054642T2 (enExample)
IL (2) IL297997A (enExample)
NZ (1) NZ762365A (enExample)
PL (1) PL3265575T3 (enExample)
PT (1) PT3265575T (enExample)
SG (2) SG11201707144VA (enExample)
SI (1) SI3265575T1 (enExample)
WO (1) WO2016141303A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
IL285403B2 (en) 2014-01-27 2023-10-01 Molecular Templates Inc Polypeptides that remove an epitope for MHC group I
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ,インク. 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ,インク. 脱免疫化された志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
EP3758752A4 (en) 2018-03-01 2021-12-15 IGM Biosciences Inc. IGM-FC AND J-CHAIN MUTATIONS AFFECTING IGM SERUM HALF-LIFE
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
JP2022505663A (ja) * 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド IgM-Fcベース及びIgA-Fcベースの多価結合分子
AU2020329301A1 (en) 2019-08-15 2022-02-17 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
CN114616031A (zh) * 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN112521508B (zh) * 2020-12-29 2021-08-03 郴州宾泽医学检验有限公司 一种cd20抗体及其治疗癌症的应用
MX2023009615A (es) * 2021-02-17 2023-08-24 Igm Biosciences Inc Moleculas de union anti-cd123 y usos de estas.
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
JP2026502759A (ja) * 2023-01-06 2026-01-27 アイジーエム バイオサイエンシズ インコーポレイテッド T細胞共刺激多量体結合分子及びその使用
AU2024355525A1 (en) * 2023-10-03 2026-04-02 Atara Biotherapeutics, Inc. Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6476198B1 (en) * 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
AU740918B2 (en) 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU2001247616B2 (en) * 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
ATE442386T1 (de) 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
AU2001272908A1 (en) 2000-05-10 2001-11-20 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
RU2004127458A (ru) 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
JP4472351B2 (ja) 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗cd74抗体およびその使用方法
ES2384168T3 (es) 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
CN101824090B (zh) 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
KR20110017020A (ko) * 2002-10-17 2011-02-18 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
DE602004027483D1 (de) 2003-05-23 2010-07-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
EP2204190A1 (en) * 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JP4671864B2 (ja) 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2586285A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
ES2829566T3 (es) 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Cd20에 대한 항체 및 그의 용도
US7919672B2 (en) * 2005-08-03 2011-04-05 Therapeutic Human Polyclonals, Inc. Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン,エルエルシー EphA2BiTE分子およびその使用
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
WO2008135963A2 (en) 2007-05-02 2008-11-13 Hemogem Inc. Fibrinogen for treatment of bleeding in trauma and platelet disorders
CN201229536Y (zh) 2008-07-03 2009-04-29 鸿富锦精密工业(深圳)有限公司 电脑机箱
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
BR112012020101A2 (pt) 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
CN104725507B (zh) 2010-10-19 2018-12-21 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CN104254544B (zh) 2012-02-08 2017-04-26 Igm生物科学有限公司 Cdim结合蛋白及其用途
US10059777B2 (en) * 2012-04-05 2018-08-28 Gottfried Himmler Secretory immunoglobulin complex
CN104379167B (zh) 2012-04-17 2018-02-13 梅奥医学教育和研究基金会 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
IN2015DN01361A (enExample) * 2012-08-02 2015-07-03 Jn Biosciences Llc
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10066238B2 (en) 2013-02-11 2018-09-04 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
CA2931641C (en) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10167333B2 (en) 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
CA2999284C (en) * 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
EP3487533A4 (en) 2016-07-20 2020-03-25 IGM Biosciences, Inc. MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF
CA3030634A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
KR20200123782A (ko) 2018-02-26 2020-10-30 아이쥐엠 바이오사이언스 인코포레이티드 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
EP3758752A4 (en) 2018-03-01 2021-12-15 IGM Biosciences Inc. IGM-FC AND J-CHAIN MUTATIONS AFFECTING IGM SERUM HALF-LIFE
JP2022505663A (ja) 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド IgM-Fcベース及びIgA-Fcベースの多価結合分子

Similar Documents

Publication Publication Date Title
JP7624484B2 (ja) 新規抗pd-l1抗体
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
US20240343810A1 (en) Multispecific antibodies for immuno-oncology
JP7461950B2 (ja) Cd3抗体およびその医薬用途
CN113874399B (zh) 抗ror1/抗cd3双特异性结合分子
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
JP2022174033A (ja) ヒト化、マウスまたはキメラ抗cd47モノクローナル抗体
JP2021058186A (ja) Ox40に対する抗体およびその使用
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
BR112021009325A2 (pt) Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
JP2022513053A (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
JP2019532619A5 (enExample)
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
WO2016141303A2 (en) Cd20 binding molecules and uses thereof
US20230192845A1 (en) Cd96-binding agents as immunomodulators
JP7836033B2 (ja) Gprc5d抗体及びその応用
WO2020114479A1 (zh) 多特异性蛋白分子
CN119948063A (zh) 结合egfr和b7-h3的双特异性抗体
JP2020515277A5 (enExample)
CN108138172A (zh) 抗体
CA3228641A1 (en) Fap/cd40 binding molecule and medicinal use thereof
CN116234572A (zh) 治疗性SIRPα抗体
KR20240055080A (ko) Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
CN112236456B (zh) 新型双特异性pd-1/lag-3抗体分子
CN120958026A (zh) Fap/4-1bb/cd40结合分子及其医药用途